Clinical Trial Update: Second-line Switch to Dolutegravir Study [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial examining switching to dolutegravir as a second-line therapy for HIV-1 infection has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Dolutegravir (dolutegravir)

Snippet

Sponsor: University of Nairobi | Conditions: HIV-1-infection | Phase 4 | Status: COMPLETED